Drug intelligence / Profile preview

piracetam

Development stage
Phase 4
Lead developer
UCB
Modality
Small Molecules
Administration
Oral, Intravenous, Intramuscular
01

Overview

Piracetam is a nootropic drug belonging to the racetams group, with the chemical name 2‑oxo‑1‑pyrrolidine acetamide. It is a cyclic derivative of gamma-Aminobutyric acid (GABA) but does not act directly on GABA receptors. Its mechanism of action is not fully understood; it modulates neuronal and vascular function and influences cognitive processes without sedative or stimulant effects. Piracetam acts as a weak positive allosteric modulator of AMPA receptors, increases acetylcholine activity via muscarinic cholinergic receptors, may affect NMDA glutamate receptors, inhibits N-type calcium channels, and increases cell membrane permeability. It has been used for cognitive disorders such as dementia and memory impairment due to cerebrovascular disease or trauma, vertigo, cortical myoclonus, dyslexia in children, sickle cell anemia-related complications, and other neurological conditions[1][3][4][7].

Brand names
NootropilNootropylNormabrainAvigilenAxonylCerebroforteEuviforGabacetGenogrisGeramNootronNorzetam脑复康
Other names
吡拉西坦2-Oxo-pyrrolidine acetamide2-Oxo-pyrrolidinylacetamide1-Pyrrolidineacetamide, 2‑oxo-PirazetamPirroxilPyracetamPyramemUCB 6215UCB6215UCB-6215吡乙酰胺酰胺吡酮吡咯乙酰胺吡烷酮醋胺乙酰胺吡咯烷酮
02

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)mAChR (Muscarinic acetylcholine receptors)AMPAR (AMPA receptor)CACNA1B (Voltage-dependent N-type calcium channel subunit alpha-1B)

Beyond the preview

Go deeper on piracetam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on piracetam.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call